(1R,2S)-2-amino-cyclopentanecarboxylic acid ethyl ester hydrochloride | 180979-15-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (1R,2S)-2-amino-cyclopentanecarboxylic acid ethyl ester hydrochloride
• 英文别名: ethyl cis-2-aminocyclopentanecarboxylate.HCl；Ethyl cis-2-amino-1-cyclopentane carboxylate hydrochloride；ethyl (1R,2S)-2-aminocyclopentane-1-carboxylate;hydrochloride
• CAS: 180979-15-1
• 化学式: C₈H₁₅NO₂*ClH
• 分子量: 193.674
• InChiKey: RYBMXCZWUCHLJB-HHQFNNIRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  52.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (1R,2S)-2-amino-cyclopentanecarboxylic acid ethyl ester hydrochloride 、 异戊醛 在 sodium acetate 、 sodium cyanoborohydride 作用下， 以 甲醇 为溶剂， 反应 16.0h， 以61%的产率得到(1R,2S)-2-(3-methyl-butylamino)-cyclopentanecarboxylic acid ethyl ester
  参考文献：
  名称：

  WO2008/73982

  摘要：

  公开号：
• 作为产物：
  描述：

  (1R,2s)-2-氨基-环戊烷羧酸乙酯 在 盐酸 作用下， 以 1,4-二氧六环 、 乙酸乙酯 为溶剂， 反应 1.0h， 生成 (1R,2S)-2-amino-cyclopentanecarboxylic acid ethyl ester hydrochloride
  参考文献：
  名称：

  WO2008/73982

  摘要：

  公开号：

文献信息

• [1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS
  申请人：Ruebsam Frank

  公开号：US20090306057A1

  公开（公告）日：2009-12-10

  The invention is directed to [1,2,4]thiadiazine 1,1-dioxide compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.

  这项发明涉及[1,2,4]噻二嗪1,1-二氧化物化合物和含有这种化合物的药物组合物，可用于治疗丙型肝炎病毒感染。
• [EN] ARYL-PHENYL-SULFONAMIDO-CYCLOALKYL COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS ARYL-PHÉNYL-SULFONAMINO-CYCLOALKYLE ET LEURS UTILISATIONS
  申请人：PIMCO 2664 LTD

  公开号：WO2010032009A1

  公开（公告）日：2010-03-25

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-cycloalkyl compounds of the following formula (collectively referred to herein as "APSAC compounds"). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, in treatment, for example, of inflammation and/or joint destruction and/or bone loss; of disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; of inflammatory and autoimmune disorders, for example, rheumatoid arthritis, psoriasis, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), atherosclerosis, inflammatory bowel disease, ankylosing spondylitis, and the like; of disorders associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, Paget's disease and the like, etc.; and of cancer, such as a haematological malignancy, a solid tumour, etc. Formula (I).

  本发明一般涉及治疗化合物领域，更具体地涉及以下化学式的某些芳基-苯基-磺酰胺基-环烷基化合物（以下统称为“APSAC化合物”）。本发明还涉及包含这种化合物的药物组合物，以及这种化合物和组合物的使用，无论是在体外还是体内，用于治疗炎症和/或关节破坏和/或骨质流失等疾病，过度和/或不适当和/或持续激活免疫系统介导的疾病，例如炎症性和自身免疫性疾病，如类风湿关节炎、银屑病、银屑病性关节炎、慢性阻塞性肺病（COPD）、动脉粥样硬化、炎症性肠病、强直性脊柱炎等；与骨质流失相关的疾病，例如类风湿性关节炎中由过度破骨细胞活动引起的骨质流失、骨质疏松症、癌症相关的骨病、帕金森病等等；以及癌症，如血液恶性肿瘤、实体肿瘤等。化学式（I）。
• Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)
  申请人：——

  公开号：US20030139388A1

  公开（公告）日：2003-07-24

  The present application describes novel cyclic hydroxamic acids of formula I: 1 or pharmaceutically acceptable salt forms thereof, wherein ring B is a 5-7 membered cyclic system containing from 0-2 heteroatoms selected from O, N, NR 1 , and S(O) p , and 0-1 carbonyl groups and the other variables are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-&agr; converting enzyme (TACE), aggrecanase or a combination thereof, pharmaceutical compositions containing the same, and methods of using the same.

  本申请描述了新型的公式I:1的环式羟羧酸，或其药用盐形式，其中环B是一个包含0-2个来自O、N、NR1和S(O)p的杂原子以及0-1个羰基的5-7元环系统，其他变量在本说明书中有定义，这些化合物可作为基质金属蛋白酶（MMP）、TNF-α转化酶（TACE）、聚集素酶或其组合的抑制剂，包含这些化合物的药物组合物，以及使用这些化合物的方法。
• Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha
  申请人：——

  公开号：US20020016336A1

  公开（公告）日：2002-02-07

  The present application describes novel cyclic &bgr;-amino acid derivatives of formula I: 1 or pharmaceutically acceptable salt forms thereof, wherein ring B is a 5-7 membered cyclic system containing from 0-2 heteroatoms selected from O, N, NR a , and S(O) p , and 0-1 carbonyl groups and the other variables are defined in the present specification, which are useful as metalloprotease and/or as TNF-&agr; inhibitors.

  本发明申请描述了新颖的环状β-氨基酸衍生物，其通式为I：1或其药学上可接受的盐形式，其中环B是含有0-2个选自O、N、NRa和S(O)p的杂原子以及0-1个羰基的5-7元环状系统，其他变量在本文中有定义，这些化合物可作为金属蛋白酶和/或TNF-α抑制剂使用。
• Estra-1,3,5(10),16-tetraene-3-carboxamide derivatives, processes for their preparation, pharmaceutical preparations comprising them and their use for preparing medicaments
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20140249119A1

  公开（公告）日：2014-09-04

  The invention relates to AKR1C3 inhibitors and to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular bleeding disorders and endometriosis.

  本发明涉及AKR1C3抑制剂及其制备工艺，以及它们在治疗和/或预防疾病方面的应用，还包括它们用于制备治疗和/或预防疾病的药物，特别是出血性疾病和子宫内膜异位症。